M. Gil
11 Papers
64 Citations
M. Gil is an academic researcher. The author has contributed to research in topics: Zoledronic acid & Breast cancer. The author has an hindex of 7, co-authored 11 publications.
Chat about Author
Papers
Breast-Cancer Adjuvant Therapy with Zoledronic Acid
Robert E. Coleman,Helen Marshall,David Cameron,D. Dodwell,Roger Burkinshaw,M. Keane,M. Gil,Stephen Houston,Robert Grieve,Peter Barrett-Lee,Diana Ritchie,Julia Pugh,Claire Gaunt,Una Rea,Jennifer Peterson,Claire Davies,Victoria Hiley,Walter M Gregory,Richard Bell +18 more
TL;DR: The routine use of zoledronic acid in the adjuvant management of breast cancer is not supported, and a prespecified boundary for lack of benefit had been crossed.
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
Robert E. Coleman,David Cameron,D. Dodwell,Richard Bell,Caroline Wilson,Emma Rathbone,Emma Rathbone,M. Keane,M. Gil,Roger Burkinshaw,Robert Grieve,Peter Barrett-Lee,Diana Ritchie,Victoria Liversedge,Samantha Hinsley,Helen Marshall +15 more
TL;DR: No overall benefit is suggested from the addition of zoledronic acid to standard adjuvant treatments for early breast cancer, however, zoledronics acid does reduce the development of bone metastases and, for women with established menopause, improved disease outcomes.
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer
Robert E. Coleman,E.J. Woodward,E.J. Woodward,Julia Brown,Julia Brown,Duncan P. Cameron,Duncan P. Cameron,Richard Bell,D. Dodwell,M. Keane,M. Gil,Claire Davies,Roger Burkinshaw,Stephen Houston,Robert Grieve,Peter Barrett-Lee,H. Thorpe +16 more
TL;DR: ZOL in the adjUvant setting is well tolerated, and can be safely administered in addition to adjuvant therapy including chemotherapy, with a low incidence of ONJ.
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).
Robert E. Coleman,Michelle Collinson,Walter M Gregory,Helen Marshall,Richard Bell,D. Dodwell,M. Keane,M. Gil,Peter Barrett-Lee,Diana Ritchie,A. Bowman,Victoria Liversedge,R De Boer,José Luís Passos-Coelho,S. O'Reilly,Gianfilippo Bertelli,Johnathan Joffe,Janet E. Brown,Caroline Wilson,Juan-Carlos Tercero,Joël Jean-Mairet,Roger R. Gomis,David Cameron +22 more
TL;DR: Disease benefits with adjuvant ZOL in postmenopausal early breast cancer persist at 10 years of follow-up, and the biomarker MAF identified a patient subgroup that derived benefit from ZOL irrespective of menopausal status.
91
Abstract S4-5: Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04)
Robert E. Coleman,H. Thorpe,David Cameron,D. Dodwell,Roger Burkinshaw,M. Keane,M. Gil,Stephen Houston,Robert Grieve,Peter Barrett-Lee,Diana Ritchie,C Davies,Richard Bell +12 more
TL;DR: The AZURE trial is an academic study designed to determine whether treatment with ZOL added to standard adjuvant therapy improves DFS and bone metastasis-free survival (BMFS) in a broader range of patients with stage II/III breast cancer.
62